
Janine Nuver

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1421075/publications.pdf Version: 2024-02-01



IANINE NUVED

#	Article	IF	CITATIONS
1	Shared-care survivorship program for testicular cancer patients: safe and feasible. ESMO Open, 2022, 7, 100488.	4.5	2
2	Change in telomere length and cardiovascular risk in testicular cancer survivors Journal of Clinical Oncology, 2022, 40, 12079-12079.	1.6	1
3	Cardiovascular disease in testicular cancer survivors: Identification of risk factors and impact on quality of life Journal of Clinical Oncology, 2022, 40, 12070-12070.	1.6	1
4	Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer. Journal of Clinical Oncology, 2021, 39, 319-327.	1.6	15
5	Successful rapid desensitization in a glioma patient with procarbazineâ€mediated anaphylaxis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1932-1933.	5.7	3
6	An aggressive poorly differentiated plurihormonal Pit-1-positive adenoma. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.5	0
7	Bariatric surgery in a testicular cancer survivor: Restoring both metabolic and testosterone status. European Journal of Cancer, 2021, 158, 12-14.	2.8	1
8	Myocardial dysfunction in longâ€ŧerm breast cancer survivors treated at ages 40–50 years. European Journal of Heart Failure, 2020, 22, 338-346.	7.1	25
9	Incidence and risk factors for contralateral testicular tumor Journal of Clinical Oncology, 2020, 38, 419-419.	1.6	0
10	Correspondence between primary and secondary care about patients with cancer: A qualitative mixed-methods analysis. European Journal of Cancer Care, 2019, 28, e12903.	1.5	12
11	Correspondence between primary and secondary care about patients with cancer: a Delphi consensus study. Supportive Care in Cancer, 2019, 27, 4199-4205.	2.2	9
12	Insulinâ€like factor 3, luteinizing hormone and testosterone in testicular cancer patients: effects of βâ€ <scp>hCG</scp> and cancer treatment. Andrology, 2019, 7, 441-448.	3.5	6
13	Life expectancy 20 years after cisplatin-based treatment for testicular cancer (TC) Journal of Clinical Oncology, 2017, 35, 4550-4550.	1.6	2
14	Safety and usefulness of patient-centered shared survivorship care after chemotherapy for testicular cancer Journal of Clinical Oncology, 2017, 35, 4561-4561.	1.6	1
15	Bleomycin-Induced Pulmonary Changes on Restaging Computed Tomography Scans in Two Thirds of Testicular Cancer Patients Show No Correlation With Fibrosis Markers. Oncologist, 2016, 21, 995-1001.	3.7	9
16	Cancer treatment induced metabolic syndrome: Improving outcome with lifestyle. Critical Reviews in Oncology/Hematology, 2016, 108, 128-136.	4.4	45
17	Variation in the HFE gene is associated with the development of bleomycin-induced pulmonary toxicity in testicular cancer patients. European Journal of Cancer, 2016, 59, 134-141.	2.8	17
18	Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy. European Journal of Cancer, 2016, 63, 180-188.	2.8	25

JANINE NUVER

#	Article	IF	CITATIONS
19	Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors. European Journal of Cancer, 2016, 54, 104-111.	2.8	7
20	Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors. Annals of Oncology, 2015, 26, 2305-2310.	1.2	61
21	Bleomycin-induced pulmonary changes on restaging CT scans: Frequency and correlation with fibrosis markers Journal of Clinical Oncology, 2015, 33, 4540-4540.	1.6	0
22	High risk vascular fingerprint in patients treated with cisplatin-based chemotherapy for testicular cancer Journal of Clinical Oncology, 2015, 33, e15556-e15556.	1.6	0
23	Cardiovascular disease after cancer therapy. European Journal of Cancer, Supplement, 2014, 12, 18-28.	2.2	110
24	Association of long-term exposure to circulating platinum with adverse late effects in testicular cancer survivors Journal of Clinical Oncology, 2012, 30, 4528-4528.	1.6	0
25	Long-Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular Cancer. Journal of Clinical Oncology, 2006, 24, 467-475.	1.6	312
26	Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients. Pharmacogenetics and Genomics, 2005, 15, 399-405.	1.5	30
27	The Metabolic Syndrome and Disturbances in Hormone Levels in Long-Term Survivors of Disseminated Testicular Cancer. Journal of Clinical Oncology, 2005, 23, 3718-3725.	1.6	185
28	Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. European Journal of Cancer, 2004, 40, 701-706.	2.8	136